AB
BCAX

Amalgamated Bank’s Bicara Therapeutics BCAX Stock Holding History

Amalgamated Bank’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-989
Closed -$17K – 2885
2025
Q4 		$17K Buy
989
+331
+50% +$5.65K ﹤0.01% 2196
2025
Q3 		$10K Hold
658
– – ﹤0.01% 2492
2025
Q2 		$6K Hold
658
– – ﹤0.01% 2702
2025
Q1 		$9K Hold
658
– – ﹤0.01% 2450
2024
Q4 		$11K Buy
+658
New +$13.7K ﹤0.01% 2411

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Amalgamated Bank's BCAX Position: Q1 2026 in Review

Amalgamated Bank sold out of Bicara Therapeutics (BCAX) in Q1 2026, closing a stake of 989 shares — an estimated $17K sold.

Amalgamated Bank first reported a position in BCAX in Q4 2024 and held it in 5 quarters. The position peaked at $17K in Q4 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Amalgamated Bank reported no remaining Bicara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 989 Bicara Therapeutics shares in Q1 2026, an estimated $17K.
  • Amalgamated Bank first reported a position in Bicara Therapeutics in Q4 2024 and held it in 5 quarters.
  • Amalgamated Bank's Bicara Therapeutics position peaked at $17K in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.